NGeneBio Sets Ex-Rights Base Price at 1404 KRW for Rights Offering, Expected Dilution of About 18%
NGeneBio has confirmed the ex-rights date of July 21, 2026 for its paid-in capital increase and set the base price at 1404 KRW.
The ex-rights base price is 17.9% lower than the previous closing price of 1710 KRW, reflecting dilution from the new share issuance.
The size and use of proceeds from the rights offering were not disclosed, but the ex-rights adjustment itself inevitably dilutes existing shareholder value.
[AI Summary]NGeneBio’s ex-rights announcement for its rights offering causes an approximate 18% price adjustment, directly diluting existing shareholder value. The lack of disclosed purpose for the capital raise makes it difficult to assess potential growth, and the near-term stock price outlook is negative.